NGeneBio Gets CE-IVD Mark for Next-Generation Sequencing Cancer Test

South Korea-based NGeneBio has received a CE-IVD mark for its OncoaccuPanel next-generation sequencing cancer test.

The OncoaccuPanel test identifies small nucleotide variants, inserts and deletions, and other mutations that can help clinicians determine the diagnosis or specific therapies for patients with solid tumors.

Founded in October 2015 as a joint venture between Seoul-based Genecurix and Korea Telecom, NGeneBio specializes in molecular diagnostics, companion diagnostics, next generation sequencing-based in vitro diagnostics panels and clinical analysis software.